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Background: Primary small cell carcinoma of the esophagus (PSCCE) is a rare and aggressive tumor with poor
prognosis. The aim of this study was to investigate the existence of EGFR, KRAS, PIK3CA and PTEN mutations in PSCCE.
Methods: Clinical–pathological data and paraffin-embedded specimens were collected from 38 patients. Exons 18 to 21
of EGFR, KRAS and PIK3CA status were analyzed by real-time PCR based on ARMS and Scorpion technology in all
patients, and the PTEN gene was also screened using real-time PCR and high-resolution melting curve analysis (HRMA).
Results: Only 1 (2.63%) out of 38 patients had EGFR mutations in L858R missense, and KRAS and PIK3CA were not found
in the mutational spot in all patients. However, PTEN mutations presented in 14 (36.84%) out of 38 patients, including
exon 5 coding for PTEN missense mutation (n =4, 10.53%), exon 6 (n =7, 18.42%), concurrent exon 5 and exon 6 (n =2,
5.26%), and exon 8 (n =1, 2.63%). Concurrent mutations of these genes were not detected in all samples. No statistically
significant associations were found between the clinicopathological features and the mutation status of PTEN.
Conclusions: The incidence of PTEN mutations in Chinese patients with PSCCE was higher than that of previous reports
in other histological subtypes of esophageal cancer.
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Primary small cell carcinoma of the esophagus (PSCCE)
is a specific histological type of esophageal malignancy and
is a rare, aggressive disease with a high metastatic rate and
poor outcome. The incidence of PSCCE is reported to be
1–1.5% of all esophageal malignancies [1] and from 0.05
to 2.4% in western populations [2], 7.6% in Chinese litera-
ture [2,3]. Several treatment options are available, includ-
ing surgery, chemotherapy, radiotherapy and concurrent
chemo-radiotherapy, but the prognosis remains poor.
Hence, it is urgent to explore novel therapeutic modalities
for patients with PSCCE.
Molecular targeted therapy is one of the new modal-
ities that have emerged in the past decade. An epidermal* Correspondence: wangge70@hotmail.com
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reproduction in any medium, provided the orgrowth factor receptor (EGFR) has been validated as a
promising therapeutic target for cancer. It has been re-
ported that EGFR expression is higher in esophageal cancer
cells than in corresponding normal tissue and EGFR muta-
tions have always been found although the incidence is low
[4-15]. And whether or not it may be potentially useful tar-
gets of therapy for esophageal cancer remains unclear.
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
(KRAS) is a critical downstream effector of the EGFR path-
way. KRAS can harbor oncogenic mutations that yield a
constitutively active protein [16]. Recently studies have in-
dicated that the presence of mutant KRAS is favorable to
one of the high-risk factors implicated in esophageal squa-
mous cell carcinoma (ESCC) development [17-21]. Mutant
Phosphatidylinositol 3-kinase CA (PIK3CA) stimulates the
AKT pathway and promotes cell growth in several cancers,
including ESCC and Non-small cell lung cancer (NSCLC)
being associated in these cases with poor prognosis [22].
Furthermore, PIK3CA mutations were always found inLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Zhang et al. BMC Cancer 2014, 14:19 Page 2 of 8
http://www.biomedcentral.com/1471-2407/14/19esophageal cancer [23,24] and further functional analyses
of the mutations are warranted to determine whether or
not they may be potentially useful targets of therapy for
esophageal cancer [25]. Phosphatase and tensin homolog
deleted on chromosome 10 (PTEN) mutation is a frequent
event in endometrial cancers. Recent reports have demon-
strateded that the presence of PTEN mutation is highly
predictive in glycogenic acanthosis of the esophagus, and
there are mutations in the PTEN gene of the ESCC cells
and that the wild type PTEN gene has important effects on
the ESCC cells in vitro and in vivo [26,27]. Whatever, these
data suggest that PTEN could be another target gene in
esophageal cancer treatment.
Mutations in KRAS, PIK3CA and PTEN genes have
recently emerged as the potential predictive factors of low/
absent response to EGFR-targeted therapy. Given that cur-
rently there is a lack of data on gene mutations associated
with EGFR, a potential target for PSCCE, except a few case
reports which lacks detailed description of the type of
esophageal cancer investigated, and the distribution of these
genes mutations in PSCCE still remains uncertain, we were
motivated to conduct this study. The present study, which
to our knowledge is the first in the world on this area, will
help to clarify the issues.
Methods
Clinical specimens
38 samples of cancer tissues were obtained from PSCCE
patients who underwent endoscopic evaluation with biopsy
and esophagectomy at Daping Hospital, Third Military
Medical University between October 2007 and June 2012.
The age of the patients ranged from 42 to 76 years (median
61.3 years). 31 (81.58%) patients were male and the rest 7
(18.42%) were female. The patients were treatment-naive
prior to the study. Esophageal biopsies were obtained via
endoscopy from the 38 patients and histopathology per-
formed. The cells, forming neoplastic formation in which
mitotic figures and intensive squeezed artefacts were
found, were round or oval-shaped and having the granular
chromatin. The cytoplasm was narrow, and nuclei ap-
peared in different shapes (Figure 1). Immunohistochemi-
cal (IHC) assay demonstrated that tumoral cells in over
95% of the 38 samples presenting chromogranin A (CgA),
Ki-67, cytokeratin (CK), and synaptophysin (Syn) with a
positive immunoreactivity. Immunoreactivity together with
thyroid transcription factor-1 (TTF-1) and CD56 were ob-
served positive in about 45% to 65%. All the cases were re-
ported as PSCCE by three independent pathologists with
knowledge of clinical data, cytological and IHC examin-
ation. The study protocol was in accordance with the
ethical guidelines of the 1995 Declaration of Helsinki
and was approved by independent ethics committees at
Daping Hospital, Third Military Medical University. Writ-
ten informed consent was obtained from the patient forthe publication of this report and any accompanying
images.
DNA isolation
Mutation analysis of these genes was performed by ex-
traction of genomic DNA from formalin-fixed, paraffin-
embedded tissue slides or sections with the use of the
QIAamp DNA FFPE Tissue Kit (Qiagen), according to the
manufacturer’s instruction. Tumor DNA was isolated from
areas which were selected under light microscopic control
by three senior pathologists and which containing at least
70% tumor cells in paraffin-embedded tumor samples.
Mutation detection
EGFR, KRAS and PIK3CA mutation analysis
Mutational analysis was performed as described previously
[17]. For EGFR mutations analysis, we used the EGFR Scor-
pions kit (DxS, Manchester, UK), which combines Scor-
pions amplification refractory mutation system (ARMS)
and Scorpions technology, to detect mutations in Real-time
Polymerase Chain Reaction (PCR) reactions. Mutant KRAS
in exon 2 was detected using a validated KRAS mutation
kit (DxS, Manchester, UK) that identifies seven somatic
mutations located in codons 12 and 13 using allele-specific
Real-Time PCR. PIK3CA mutations in exons 9 and 20 were
detected using a validated PIK3CA mutation kit (DxS,
Manchester, UK) that identifies three somatic mutations
(H1047R, E542 and E545) by Real-Time PCR based on
ARMS and Scorpion technology. All the analysis of these
genes mutations were performed in an ABI Prism 7700 se-
quence detector (Applied Biosystems). SDS2.0 software
(Applied Biosystems) was performed for data analysis ac-
cording to the manufacturer’s instructions. Each sample
was analyzed in triplicate or duplicate.
PTEN mutation analysis
PTEN mutations in exons 5, 6 and 8 were evaluated using
a method previously published [28]. High-resolution melt-
ing analysis(HRMA) was performed on genomic DNA
prepared from scraped paraffin slides. Two round PCR
was done using 6 primer sets covering three exons of the
PTEN gene. The following primer sets for Exon 5 were
used: PTEN-F (forward) 5′ACC TGT TAA GTT TGT
ATG CAA C3′, PTEN-R (reverse) 3′TCC AGG AAG
AGG AAA GGA AA5′, Exon 6, PTEN-F 5′CAT AGC
AAT TTA GTG AAA TAA CT3′; PTEN-R 3′GAT ATG
GTT AAG AAA ACT GTT C5′, Exon 8, PTEN-F 5′CTC
AGA TTG CCT TAT AAT AGT C3′; PTEN-R 3′TCA
TGT TAC TGC TAC GTA AAC5′. All exons were ampli-
fied with the following PCR conditions: pretreatment at
94°C for 4 minutes, 35 cycles of amplification, and a single
10 minute final extension procedure. Each of these 35 cy-
cles consisted of a denaturing step at 94°C for 1 minute,
an annealing step of one minute (54°C for exons 5 and 8;
Figure 1 A representative case of primary small cell carcinoma of the esophagus. Biopsy materials were shown in the histopathologic
examination, and tumoral cells in the sample indicated CK, CgA, CD56, Syn, TTF-1 and Ki-67 with a positive immunoreactivity by immunohistochemical
examination. (Magnification, ×200).
Table 1 The frequency of EGFR, KRAS, PIK3CA and PTEN
mutations according to different patterns (n = 38)
Patterns of mutations No. of cases (%)
EGFR
Exon 18 (G719S) 0












Exon 9 (E542/545) 0
Exon 20 (H1047R) 0
PTEN
Exon 5 4 (10.53)
Exon 6 7 (18.42)
Exon 8 1 (2.63)
Exon 5 and Exon 6 2 (5.26)
2 patients also mutated in both Exon 5 and Exon 6 for PTEN.
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minute. After the final extension, an additional denatur-
ation step at 95°C for 30 s was carried out. Subsequently,
the PCR products were briefly centrifuged and were used
directly for high-resolution melting using the LightScanner®
instrument (Idaho Technology, Inc.). LightScanner® analyt-
ical software with Call-IT™ 2.0 (Idaho Technology, Inc.)
was performed for data analysis according to the manufac-
turer’s instructions. All HRM assays were replicated two to
three times for each sample.
Statistical analysis
All the data were processed using SPSS13.0 software.
Chi-square (X2) test was performed to assess the signifi-
cance of the association between PTEN mutations and
other clinical pathologic characteristics, e.g. gender, age
(<60 vs. ≥60), tumor location (upper vs. middle vs. lower
third), and TNM stage (cI vs. cIIa-cIIb vs.cIII). All P-
values < 0.05 were considered as statistically significant.
Results
The presence of EGFR, KRAS, PIK3CA and PTEN mu-
tations in 38 patients were listed in Table 1. Each patient
was represented only once, where for each type of ma-
terial the information from all the patient’s samples was
merged. An EGFR mutation was identified in 1(2.63%)
of the 38 PSCCE patients, resulting in L858R missense
mutation in exon 21. No mutation was found in exons
18,19 and 20. We either did not found KRAS mutations
in codons 12, 13 and PIK3CA mutations in exon 9
(E542/E545) and exon 20 (H1047R) in all samples. PTEN
mutations were detected in 14(36.84%) out of 38 patients
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mutation (n =4, 10.53%), exon 6 (n =7, 18.42%), concur-
rent exon 5 and exon 6 (n =2, 5.26%), and exon 8 (n =1,
2.63%). No concurrent mutations of these genes were de-
tected in all samples. Moreover, there were no significant
associations between PTEN mutations and clinical patho-
logic characteristics, e.g. gender, age, tumor location and
TNM stage (Table 2).
Discussion
China is an endemic region for esophageal cancers. The
incidence has been reported as165–200/100,000 in China,
Japan and Eastern Turkey, while it is only 3/100,000 in
Europe and USA [2]. Recently many published reports
have demonstrated that EGFR mutations were detected in
EC cell lines and patients with EC (Table 3). A phase II
study of advanced EC treatment by gefitinib indicated that
patients with ESCC had a higher disease control rate [7].
Another phase II trial using gefitinib in advanced EAC
showed that gefitinib (500 mg/d) were an active and gen-
erally well-tolerated treatment for EAC [8]. However,Figure 2 Amplification plots for PTEN mutations in exon 5,6,8 using H
sample containing no mutated in PTEN gene. A, exon 5; B, exon 6; C, exon
and exon 6 in PTEN gene. D, exon 5; E, exon 6; F, exon 8. (G,H,I). Amplifica
exon 5; H, exon 6; I, exon 8. The Y-axis shows the relative fluorescence for a m
signal, X-axis shows the temperature (°C). Each sample was analyzed in triplicawhether similar results exist in patients with PSCCE re-
mains unclear. To date, the mutation status of EGFR and
EGFR related genes in patients with PSCCE have not been
reported because of the rare incidence of the specific
histological type of esophageal cancer worldwide. In fact,
the reported incidence of PSCCE among all esophageal
malignancies is higher in Chinese population than in
Caucasians [2]. In this study, we found that only 2.63%
of 38 patients with PSCCE carring EGFR mutations,
consistent with data that reported in the previous studies
on other histological types of EC [9,14,24], but signifi-
cantly different from other reports (Table 3) . Possible rea-
sons for the discrepancy are that ethnic differences in the
distribution of the EGFR mutations in EC may exist, and
the sensitivity of technique used for mutation detection
differs. Furthermore, the only one patient with PSCCE
identified for EGFR mutation was L858R missense muta-
tion in exon 21, termed as gefitinib-associated mutations.
This suggests the gefitinib-based small molecular target
therapy possibly can be appropriately applied in treating
PSCCE patients that harbor this specific mutation as well.igh-resolution melting analysis. (A,B,C). Amplification plots for a
8. (D,E,F). Amplification plots for a sample containing mutated exon 5
tion plots for a sample containing a mutated exon 8 in PTEN gene. G,
easurement of the change in fluorescent signal versus a passive reference
te or duplicate.
Table 2 Correlations between PTEN mutations and
clinical pathologic characteristics of all patients with
PSCCE (n = 38)
Characteristic All patients PTEN mutation X2 P
valueNo. of cases No. of cases (%)
Gender
Male 31 12 (38.71) 0.252 0.615
Female 7 2 (28.57)
Age
<60 16 7 (43.75) 0.567 0.452
≥60 22 7 (31.82)
Tumor location
Upper 1/3 4 1 (25) 0.634 0.728
Middle 1/3 23 8 (34.78)
Lower 1/3 11 5 (45.45)
TNM stage
cI 3 1 (33.33) 0.866 0.648
cIIa-cIIb 17 5 (29.41)
cIII 18 8 (44.44)
TNM stage: The AJCC (6th edition) was used for staging. Abbreviations: c, clinical.
P-values < 0.05 were considered as statistically significant.
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on ligand binding, triggers two main signaling pathways.
These include the RAS-RAF-MAPK mainly involved in
cell proliferation, and the PI3K/PTEN/AKT signaling path-
way, mainly involved in cell survival and motility-invasion.
In our study, KRAS mutations in codons 12 and 13 were
not involved in PSCCE. Although published reports have
shown the mutations of KRAS were always detected in the
EC (Table 3), the incidence varied among different histo-
logical subtypes [29]. These findings indicated that KRAS
mutations are a rare event in the carcinogenesis of PSCCE
and tumorigenic effects of KRAS gene are histology spe-
cific in EC. In terms of therapeutic implications, this also
suggests that PSCCE patients with mutated KRAS should
gain little or no benefit from RAS-targeted therapy.
In addition to KRAS, the EGF receptor also activates
the PI3K/PTEN/AKT signaling pathway. The latter can
be oncogenically deregulated either by activating muta-
tions in the PIK3CA or by inactivation of the PTEN
phosphatase. The PIK3CA gene encodes the p110α cata-
lytic subunit of PI3K that regulates the PI3K/AKT path-
ways, known to play a critical role in cancer onset and
progression. A novel candidate tumor suppressor gene,
PTEN gene, known as another effector of PI3K/PTEN/
AKT pathway, is always lost by mutations, deletions or
promoter methylation silencing at high frequency in
many primary and metastatic human cancers, which are
important mechanisms for cell cycle progression, survival,
metabolism and migration. In this study, PIK3CA muta-
tions in exons 9, 20 did not occur in PSCCE, but 36.84%(14 of 38 patients) of the PSCCE samples were found
harboring PTEN mutations. These findings indicate that
PIK3CA/PTEN/AKT pathway may be an important path-
way for effect in response of EGFR targeted therapy in
PSCCE, and the mainly target effector is not PIK3CA
but PTEN.
PTEN mutations have been identified in numerous hu-
man malignancies, including brain, ovary and prostate can-
cers, but they are rarely seen in carcinomas arising from
the head and neck region (including esophagus) [26-28].
Hu et al. reported a mutation incidence of only 3.03% in
33 ESCCs [28] and no mutations were detected in the hot
spot exon 5 (Table 3). In contrast, a recently study reported
by Hou et al. [26] found high-mutations incidence of
PTEN in three cells of ESCC and that the elevated expres-
sion level of the wild type PTEN gene in ESCC cells may
increase the sensitivity of the cancer cells to chemothera-
peutic drugs (Table 3). Interestingly, 36.84% of the PSCCE
samples were found harboring PTEN mutations, much
higher than the incidence reported previously in ESCC and
other tumors. Explanations for the difference include: (1)
High-resolution melting (HRM) analysis might be more
sensitive than direct sequencing. (2) Mutation of PTEN
gene may be the most frequent molecular event in PSCCE.
Although the significance of this mutation remains un-
certain nowadays, it is likely to play a major role in the
carcinogenesis of PSCCE. This is because the mutation
is in the sequence encoding the putative phosphatase
domain and the hot spots, including exon 5 (10.53%),
exon 6 (18.42%), concurrent exon 5 and exon 6 (5.26%),
and exon 8 (n =1, 2.63%). However, whether these
mutations in the intron affects transcriptional or post-
transcriptional modulation is still to be elucidated, and
their relevance for EGFR targeted therapy in PSCCE have
not been investigated thus far. Accordingly, further func-
tional analyses of the PI3K/PTEN/AKT pathway in PSCCE
are warranted to determine whether or not they may be
potentially useful targets of therapy for PSCCE.
In the present study, we did not find any significant
correlations between the clinicopathological features and
the mutation status of PTEN (Table 2), which may be
partly due to the relatively small sample size. Larger stud-
ies are needed to draw a firm conclusion on these issues.
Nevertheless, we invoke caution as there are some ca-
veats involved in this study. First, the data presented here,
such as treatment details, survival, and disease control are
not enough to draw firm conclusions about whether the
mutations of these genes can serve as a molecular classi-
fier that correlates with TKIs responsiveness in PSCCE
and, therefore, further studies involving larger studies will
be required for an in-depth analysis. Next, our work, even
though interested in providing evidence for a newly found
high incidence of PTEN mutation in PSCCE, is rather pre-
liminary at this stage and a detailed characterization of the
Table 3 Studies on EGFR, KRAS, PIK3CA and PTEN mutations in Esophageal cancer
Gene Reference No. Pathology Exon
examined
Mutated codon with amino acid Mutation detated N (%)
EGFR Kwak et al. [4] 17 EAC 18-21 L858R, E746-A750del 2 (11.76)
Guo et al. [6] 10 EAC 18-21 A734P 1 (10.00)
57 ESCC E872, G873, P753 3 (5.26)
17 ESCC (cell line) S768I (Exon20) 1 (5.88)
Janmaat et al. [7] 26 NR 18-21 - 0
Hanawa et al. [15] 40 ESCC 19,21 - 0
Puhringer et al. [9] 105 BAC 19,21 K754 1 (0.95)
Sudo et al. [5] 1 EAC (cell line) 18-21 2607G > A (Exon20) 1 (100)
18 ESCC (cell line) NR 2 (11.11)
50 NR G719D 1 (2.00)
Mir et al. [14] 54 ESCC 18-21 codon 746–750, codon 753, codon
719 (Exon 19)
3 (5.56)
Sunpaweravong et al. [13] 48 ESCC 19,21 - 0
Kaneko et al. [12] 57 ESCC 18-21 codon 787 (Exon 20) 19 (33.33)
Marx et al. [19] 20 BAC 18-21 - 0
Liu et al. [11] 50 ESCC 18-21 G719X, L858R, Exon9 in-frame deletion 7 (14.00)
Tasioudi et al. [20] 44 ESCC 18-21 - 0
Wang et al. [10] 65 adenocarcinoma of
esophagogastric junction
18-21 codon 787 2361G- > A (Exon20) 19 (29.23)
Maeng et al. [23] 70 ESCC NR P733L 1 (1.43)
Kato et al. [29] 107 ESCC NR del745-750 1 (0.93)
KRAS Lord et al. [21] 23 EAC 2 Codon12 7 (30.43)
Janmaat et al. [8] 23 NR 2 Codon12,13 2 (8.70)
Lyronis et al. [18] 30 ESCC 2 Codon12 5 (16.67)
Marx et al. [19] 20 BAC 2-3 NR 1 (5.00)
Liu et al. [11] 50 ESCC 2 Codon12 6 (12.00)
Tasioudi et al. [20] 44 ESCC 2 Codon12 1 (2.27)
PIK3CA Phillips et al. [24] 35 ESCC 1-20 G1624A, G1633A, G1635A (Exon9)
C1027T (Exon4)
4 (11.43)
50 EAC G1624A (Exon9) 3 (6.00)
17 BAC - 0
Janmaat et al. [7] 24 NR 9,20 - 0
Mori et al. [25] 88 ESCC 9,20 E545K,E545Q(Exon9) 2 (2.27)
2 ESCC (cell line) E545K, E545Q(Exon9) 2 (100)
Akagi et al. [22] 52 ESCC 1,9,20 Exon9 4 (7.69)
Maeng et al. [23] 70 ESCC 9,20 E545K, E542K (Exon9), H1047R,
H1047L (Exon20)
9 (12.86)
PTEN Hu et al. [28] 33 ESCC 1-9 802-29 T - > C (Exon7) 1 (3.03)
492 + 8 T-deletion (Exon5) 33 (100)
Hou et al. [26] 3 ESCC (cell line) 1-9 Exon2,5,6,8 in EC907 cells 3 (100)
Exon5,8,9 in Eca cells
Exon6,8,9 in EC1 cells
BAC, Barrett’s adenocarcinomas; EAC, esophageal adenocarcinoma; EC, esophageal carcinoma; EGFR, epidermal growth factor receptor; ESCC, esophageal squamous cell
carcinoma; NR, not reported; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; PIK3CA , Phosphatidylinositol 3-kinase CA; PTEN, Phosphatase and tensin
homologue deleted on chromosome 10.
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perimental data for better understanding the functional
role and significance of PTEN mutation in PSCCE.
Conclusions
Our study is the first report of mutational analysis of
EGFR, KRAS, PIK3CA and PTEN in a number of patients
with PSCCE. These results have indicated that a high-
incidence of PTEN mutation other than EGFR, KRAS or
PIK3CA mutations in PSCCE. This suggests that PTEN is
a potential target for PSCCE in the future. Furthermore,
EGFR mutations in PSCCE are rare but do exist, especially
gefitinib associated mutations such as L858R, therefore
gefitinib-based gene targeted therapy at EGFR but not
KRAS and PIK3CA genes, probably should be included in
this carcinoma treatment regimens for patients harboring
L858R mutation.
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